...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's Lead BET Inhibitor ZEN-3694 is Currently Being Evaluated in a Phase 2 Metastatic Prostate Cancer Clinical Trial; Phase 1b/2 TNBC trial with ZEN-3694 and Pfizer’s PARPi, talazoparib, to start in April 2019.
fast facts
- name Zenith Epigenetics
- symbol "ZZXY"
- exchange OTCBB
- financials View Filings
- shares outstanding 129,170,628
- industry Technology & Medical
- transfer agent Computershare Trust Company of Canada
- website http://www.zenithepigenet...
recent updates
-
WebLink -
BIO CEO Slides 2/12/2019 -
WebLink -
Zenith Biotech Showcase 1/8/2019 -
WebLink -
BIO-Europe Nov 6, 2018 -
-
most recent messages
